Donor immune cells target hard-to-treat leukemia in new safety trial
NCT ID NCT06326008
First seen Mar 15, 2026 · Last updated May 21, 2026 · Updated 6 times
Summary
This study tests a two-step treatment for people with a type of leukemia that has come back or not responded to standard care. First, participants receive donor immune cells (CAR T cells) that target a protein called CD19 on cancer cells, followed by a stem cell transplant from the same donor. Later, they get a second dose of donor CAR T cells targeting a different protein (CD22). The main goal is to check safety and side effects in about 48 people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Conditions
Explore the condition pages connected to this study.